ArticleWorld journal of diabetes2026
Neuroprotective potential of a plant-based intervention in diabetic neuropathy: Biochemical and behavioral insights from a streptozotocin-induced rat model.
Article in World journal of diabetes, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDiabetic neuropathy is a neurodegenerative complication of diabetes mellitus that occurs due to various factors, with oxidative stress, neuroinflammation and neurotrophic signalling impairment being the major causes.
aimTo evaluate the neuroprotective effects of a polyherbal extract (PHE) prepared from
methodsType 2 diabetes was induced in rats with a single intraperitoneal injection of streptozotocin, and those with fasting blood glucose levels of > 250 mg/dL were included for further studies. The animals were categorised into five groups: Control, diabetic, diabetic + PHE, control + PHE and diabetic + metformin. These treatments were administered orally for 8 weeks. Behavioral tests comprised the hot plate, tail-flick, acetone drop and rotarod tests. Serum glucose, insulin, glycosylated haemoglobin and lipid profile analyses were performed, along with oxidative stress (malondialdehyde, reduced glutathione, superoxide dismutase, catalase and glutathione-S-transferase) and pro-inflammatory (tumour necrosis factor-α and interleukin-6) markers. Neurotrophic factors were measured, and the pancreas, liver and sciatic nerve were histologically examined.
resultsThis study demonstrated that PHE exerts a significant metabolic regulatory effect in streptozotocin-induced diabetic rat models. PHE treatment led to a marked reduction of 30.17% in fasting blood glucose levels, indicating potent antihyperglycemic activity, and also restored the lipid profile, enhanced antioxidant defenses, and reduced neuroinflammation. Serum insulin levels were significantly increased in diabetic rats receiving PHE, suggesting potential stimulation or preservation of pancreatic β-cells. Furthermore, behavioral impairments and histological damage were notably reversed following PHE administration.
conclusionThe PHE derived from
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.